NOACs Beat Warfarin on Cognition and Outcomes in AF Plus Alzheimer's
This Swedish registry analysis addresses a near-complete evidence gap on anticoagulation choice in patients with coexisting atrial fibrillation and Alzheimer's disease, favoring non-vitamin K oral anticoagulants over warfarin and no anticoagulation across cognitive, thromboembolic, and safety endpoints.
📅 Journal publication: Aug 12, 2026·Last updated: Oct 6, 2026
NOACs slow cognitive decline in AF with Alzheimer's disease.
Oral anticoagulants can impact both cognitive outcomes and overall clinical profiles in patients with atrial fibrillation (AF) and Alzheimer's disease (AD). Non-vitamin K oral anticoagulants (NOACs) resulted in slower cognitive decline and reduced risks of mortality, ischemic stroke, and fractures compared to non-use or warfarin. This study suggests NOACs may offer better outcomes than warfarin in AF patients with AD, with a comparable safety profile. NOACs may improve cognitive and clinical outcomes in patients with both AF and AD.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zhu N, Xu H, Garcia-Ptacek S, Mitra S, Eriksdotter M
Citation:Zhu N, Xu H, Garcia-Ptacek S, et al. Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study. European heart journal. 2026. doi:10.1093/eurheartj/ehag584